Table 2.
Multivariable linear regression analysis for log-transformed EPO.
| Variable | Standardized β-coefficient | 95% CI | P value |
|---|---|---|---|
| Age | 0.14 | 0.03–0.24 | 0.01 |
| Male sex | 0.10 | −0.01–0.22 | 0.07 |
| BMI | 0.16 | 0.04–0.29 | 0.01 |
| eGFR | 0.20 | 0.07–0.33 | 0.02 |
| Log UACR | 0.01 | −0.14–0.17 | 0.87 |
| Log u-LFABP | −0.02 | −0.13–0.10 | 0.78 |
| Hemoglobin | −0.33 | −0.45–0.20 | <0.01 |
| HbA1c | −0.01 | −0.13–0.11 | 0.85 |
| Log ferritin | −0.32 | −0.45–0.20 | <0.01 |
| Smoking | 0.00 | −0.09–0.09 | 0.93 |
| Log CRP | 0.12 | 0.01–0.23 | 0.04 |
| Log FGF23 | 0.07 | −0.06–0.19 | 0.30 |
| ACEI/ARB | −0.07 | −0.18–0.05 | 0.25 |
| Previous CVD | 0.03 | −0.07–0.14 | 0.54 |
EPO, erythropoietin; CI, confidence interval; BMI, body mass index; eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio; u-LFABP, urinary liver-type fatty acid-binding protein; HbA1c: hemoglobin A1c; CRP, C-reactive protein; FGF23, fibroblast growth factor 23; ACE/ARB, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; CVD, cardiovascular disease.